Accord Healthcare has struck a European licensing deal with Myovant Sciences for its Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer. The move comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer treatment in the US.
Accord Healthcare has struck a licensing deal with Myovant Sciences that will give Accord exclusive European commercialization rights for the Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer.
The move bolsters Accord’s oncology offering and comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
